Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).

NCT03478254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-01-11

Study results available
· View outcomes & findings →

Summary

Observational study about adherence to guidelines for Influenza, Pneumococcal and Hepatitis B Vaccination in adult patients with type 1 Diabetes mellitus.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL

Influenza vaccination

Correct influenza vaccination status was considered in the following situation: \- Received at least one Influenza vaccine dose in the last year.

BIOLOGICAL

Pneumococcal vaccination

Correct pneumococal vaccination status was considered if a subject received at least one of the following options: * One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. * One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months. * One PPSV 23 dose in the last 5 years. * One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year.

BIOLOGICAL

Hepatitis B Virus (HBV) vaccination

Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation: .- Received at least three consecutive doses of HBV vaccine during six consecutive months.

Sponsors & Collaborators

  • Castilla-La Mancha Health Service

    collaborator OTHER
  • University of Castilla-La Mancha

    collaborator OTHER
  • Jesús Moreno Fernández

    lead OTHER

Principal Investigators

  • Elena M Ortega Rodrigo · University of Castilla-La Mancha

  • Jose Alberto Garcia Seco, RN · University of Castilla-La Mancha

  • Fernando Garcia Seco · Universidad de Córdoba

  • Angela M Seco Segura, RN · Castilla-La Mancha Health Service

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-12-01
Completion
2018-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478254 on ClinicalTrials.gov